Abstract:Abstract rRNA modification are a crucial step in ribosome assembly and function. Small nucleolar RNAs select which nucleotides in rRNAs get modified. Typically, C/D box snoRNAs are implicated in 2’-O-ribose methylation (2’Omet) while H/ACA box snoRNAs are responsible for pseudo-uridylations. Alterations in snoRNA expression have been described in multiple tumor types while distinct snoRNAs have been linked to cancer-relevant phenotypes. Our initial study on snoRNA expression using a dedicated Ampliseq platform revealed a specific glioma stem cell (GSC) signature. We propose this snoRNA signature creates a unique rRNA modification pattern that shapes the ribosome, favoring the translation of genes in pathways critical for GSC growth and survival. We will expand our study and characterize the expression profile of snoRNAs and 2’Omethylation in a large panel of GBM cells, GSCs, neuronal precursor cells (NPCs), astrocytes, and normal brain tissues. Next, we will select snoRNAs displaying differential expression in GSCs and determine if changes in their levels affect proliferation, viability, response to temozolomide and radiation, and translation. We and others have observed that the integrity of protein complexes that regulate ribosomal biogenesis depends on PolyADP-ribosylation (PARylation)and PAR-binding. In agreement, genomic screenings determined that multiple genes regulating ribosome biogenesis confer sensitivity to PARP inhibitors. These findings offer a therapeutic opportunity. We will investigate the functional impact of PARylation on rRNA modification by determining the effect of PARP inhibitors on snoRNP assembly and 2’Omethylation. Finally, we will test the hypothesis that PARP and ribosome biogenesis inhibitor combinations would be more effective than PARP inhibition alone in treating GBM. Citation Format: Sujash Chatterjee, Scott Kuersten, Christina Middle, Morgan Roos, Pedro A. Galante, Gabriela Guardia, Luiz Penalva. The role of snoRNAs in GBM cells, GSCs, neuronal precursor cells (NPCs), astrocytes, and normal brain tissues [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5446.

The role of OncoSnoRNAs and Ribosomal RNA 2’-O-methylation in Cancer

The emerging roles of N6-methyladenosine RNA methylation in human cancers

Ribosomal RNA 2′O-methylation as a novel layer of inter-tumour heterogeneity in breast cancer

Role of Main RNA Modifications in Cancer: N6-methyladenosine, 5-Methylcytosine, and Pseudouridine

SnoRNA in Cancer Progression, Metastasis and Immunotherapy Response

Emerging Roles of RNA Methylation in Gastrointestinal Cancers

Influence of RNA Methylation on Cancerous Cells: A Prospective Approach for Alteration of In Vivo Cellular Composition

NSUN2-mediated RNA methylation: Molecular mechanisms and clinical relevance in cancer

Critical Roles and Clinical Perspectives of RNA Methylation in Cancer

RNA methylation and breast cancer: insights into m6A, m7G and m5C

The role of RNA methylation in tumor immunity and its potential in immunotherapy

RNA methylations in human cancers

The role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities

Novel Cancer-Promoting Functions and Mechanisms for snoRNAs

Decoding the ribosome's hidden language: rRNA modifications as key players in cancer dynamics and targeted therapies

SNORD88C guided 2′-O-methylation of 28S rRNA regulates SCD1 translation to inhibit autophagy and promote growth and metastasis in non-small cell lung cancer

Abstract 5446: The role of snoRNAs in GBM cells, GSCs, neuronal precursor cells (NPCs), astrocytes, and normal brain tissues

Ribosome biogenesis in cancer: new players and therapeutic avenues

Non-coding RNAs, epigenetics, and cancer: tying it all together

The Critical Role of RNA m6A Methylation in Cancer

Roles of RNA Methylation on Tumor Immunity and Clinical Implications